Literature DB >> 16155433

Nonmolecular treatment for muscular dystrophies.

Kate Bushby1, Volker Straub.   

Abstract

PURPOSE OF REVIEW: This review highlights emerging evidence on the management of patients with muscular dystrophies. RECENT
FINDINGS: New diagnostic modalities based on muscle biopsy and DNA analysis mean that diagnoses within the heterogeneous group of muscular dystrophies can be much more precise; also, as the phenotypes associated with these different disorders are clarified, new management implications can be recognized. At the same time, the spread of evidence based medicine into this area has led to an increase in clinical trial activity and the development of evidence based guidelines. Because many if not all muscular dystrophies are multisystem disorders, these guidelines relate not only to the limited number of interventions aimed at improving strength but also to the management of potentially life threatening complications.
SUMMARY: Because specific diagnoses carry specific management implications in many areas for these hitherto rather neglected disorders, a more proactive approach to patients with muscular dystrophies is needed. Complications involving, for example, the cardiovascular, respiratory and gastrointestinal systems may need to be sought and actively managed, whereas caution for complications of anaesthesia and other interventions may also be necessary. However, areas remain where there is little evidence from which practice guidelines can be developed and these will need to be addressed with well planned clinical trials.

Entities:  

Mesh:

Year:  2005        PMID: 16155433     DOI: 10.1097/01.wco.0000181326.86292.aa

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  4 in total

Review 1.  Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy.

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2006-07-28       Impact factor: 2.698

Review 2.  Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies.

Authors:  Volker Straub; Kate Bushby
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

3.  Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice.

Authors:  Anna Cozzoli; Beatrice Nico; Valeriana Teresa Sblendorio; Roberta Francesca Capogrosso; Maria Maddalena Dinardo; Vito Longo; Sara Gagliardi; Monica Montagnani; Annamaria De Luca
Journal:  Pharmacol Res       Date:  2011-06-13       Impact factor: 7.658

4.  Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers.

Authors:  Jon Tinsley; Neil Robinson; Kay E Davies
Journal:  J Clin Pharmacol       Date:  2015-02-20       Impact factor: 3.126

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.